title: Irreversible modification of the voltage-sensitive calcium channel by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ).
abstract: N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) inhibited, in vitro, the specific binding of three structurally distinct L-type Ca2+ channel ligands, (+)[3H]PN 200,110, [3H]desmethoxyverapamil and [3H]cis-diltiazem to guinea pig ileal longitudinal smooth muscle. Maximum tension responses to Ca2+ in a K(+)-depolarized functional smooth muscle preparation were reduced in a concentration-dependent manner following pretreatment with EEDQ and washout. Microsomal membranes prepared from smooth muscle pretreated with EEDQ followed by extensive washout showed a significant reduction in the amount of (+)[3H]PN 200,110 bound without change of ligand affinity. Similar results were obtained in cardiac ventricle microsomes. Preincubation with verapamil (1 x 10(-5) M) largely prevented this reduction in [3H]PN 200,110 binding sites by EEDQ. 45Ca2+ uptake in cortical synaptosomes during 1-sec depolarization following 68.5 mM K+ was also inhibited by EEDQ. Specific binding of [125I]omega-conotoxin GVIA to rat cerebral cortex membranes was inhibited by EEDQ, also in an apparently irreversible manner as seen by the marked reduction in binding site density with no significant change in the KD value. These observations indicate that EEDQ blocks Ca2+ channel function and reduces irreversibly both 1,4-dihydropyridine and omega-conotoxin GVIA binding sites.
authors.affiliation: Department of Biochemical Pharmacology, School of Pharmacy, State University of New York, Buffalo 14260.
authors.forename: M
authors.initials: M
authors.lastname: Gopalakrishnan
authors.forename: D J
authors.initials: DJ
authors.lastname: Triggle
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000818:Animals; D002118:Calcium / Q000378:metabolism; D015220:Calcium Channels / Q000187:drug effects*; D006168:Guinea Pigs; D017275:Isradipine; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D010069:Oxadiazoles / Q000378:metabolism; D010456:Peptides, Cyclic / Q000378:metabolism; D011804:Quinolines / Q000494:pharmacology*; D020866:omega-Conotoxin GVIA
chemical_list: D000317:Adrenergic alpha-Antagonists; D015220:Calcium Channels; D010069:Oxadiazoles; D010456:Peptides, Cyclic; D011804:Quinolines; C000470:EEDQ; D020866:omega-Conotoxin GVIA; D002118:Calcium; D017275:Isradipine